Value of prostate-specific antigen as a tumor marker

Area of Science:

• Oncology
• Biochemistry
• Urology

Background:

• Prostate-specific antigen (PSA) is a crucial biomarker in prostate cancer management.
• Elevated PSA levels can occur in non-cancerous conditions like benign prostatic hyperplasia, leading to diagnostic challenges.
• The reliability of PSA for individual tumor staging and prognosis requires careful consideration.

Purpose of the Study:

• To evaluate the diagnostic utility and limitations of prostate-specific antigen (PSA) as a tumor marker for prostate cancer.
• To explore the correlation between serum PSA concentrations and clinical stage, bone scan results, and patient prognosis.
• To assess the effectiveness of PSA in monitoring patients after definitive prostate cancer therapy.

Main Methods:

• Review of existing literature on prostate-specific antigen (PSA) in prostate cancer.
• Analysis of the relationship between serum PSA levels and various clinical parameters.
• Evaluation of PSA's role in disease staging, prognosis prediction, and post-treatment surveillance.

Main Results:

• Serum PSA concentration correlates with tumor stage but is not fully reliable for individual staging.
• Low PSA levels (<20 ng/ml) in untreated prostate cancer may predict negative bone scans.
• PSA is a sensitive marker for monitoring treatment response, though PSA-negative recurrences can occur.

Conclusions:

• Prostate-specific antigen (PSA) is an important, yet imperfect, tumor marker for prostate cancer.
• PSA aids in predicting bone scan outcomes and patient prognosis, enhancing post-therapy monitoring.
• Despite its sensitivity, the possibility of PSA-negative recurrence necessitates comprehensive follow-up strategies.